Try a new search

Format these results:

Searched for:

in-biosketch:true

person:segevd01

Total Results:

1181


ARTIFICIAL INTELLIGENCE: THE NEWEST MEMBER OF THE LIVER TRANSPLANT EVALUATION TEAM? [Meeting Abstract]

Strauss, Alexandra T.; Sidoti, Carolyn N.; Jain, Vedant S.; Sung, Hannah C.; Purnell, Tanjala S.; Gurses, Ayse; Gurakar, Ahmet; Jackson, John; Levan, Macey L.; Gray, Stephen H.; Hamilton, James P.; Segev, Dorry L.; Wang, Jacqueline G.; Hinson, Jeremiah; Malinsky, Daniel S.; Levin, Scott
ISI:000707188002017
ISSN: 0270-9139
CID: 5133342

TACKLING PERSISTENT HEALTH DISPARITIES IN THE LIVER TRANSPLANT EVALUATION PROCESS: A MULTI-CENTER ANALYSIS OF PROVIDER PERSPECTIVES ON MECHANISMS AND OPPORTUNITIES TO ADVANCE EQUITY [Meeting Abstract]

Strauss, Alexandra T.; Sidoti, Carolyn N.; Jain, Vedant S.; Sung, Hannah C.; Gurses, Ayse; Jackson, John; Levan, Macey L.; Levin, Scott; Gray, Stephen H.; Segev, Dorry L.; Gurakar, Ahmet; Wang, Jacqueline G.; Hamilton, James P.; Purnell, Tanjala S.
ISI:000707188000179
ISSN: 0270-9139
CID: 5133332

Discovered cancers at postmortem donor examination: A starting point for quality improvement of donor assessment

Girolami, Ilaria; Neil, Desley; Segev, Dorry Lidor; Furian, Lucrezia; Zaza, Gianluigi; Boggi, Ugo; Gambaro, Giovanni; De Feo, Tullia; Casartelli-Liviero, Marilena; Cardillo, Massimo; Lombardini, Letizia; Zampicinini, Laura; D'Errico, Antonietta; Eccher, Albino
BACKGROUND:clinical and imaging investigations allow a detailed assessment of an organ donor, but a quota of cancer still elude detection. Complete autopsy of donors is even less frequently performed, due to economic issues and increasing availability of high-quality imaging. The aim of this study is to gather evidence from the literature on donor malignancy discovered at autopsy following organ donation and to discuss the utility and limitations of autopsy practice in the field of transplantation. METHODS:A systematic search according to PRISMA guidelines was carried out in Pubmed and Embase databases until September 2020 to select articles with reporting of cancer discovered in a donor at postmortem examination. Cancer discover in not-transplant setting were excluded. A descriptive synthesis was provided. RESULTS:Of 7388 articles after duplicates removal, 56 were included. Fifty-one studies reported on complete autopsy, while 5 dealt only with limited autopsy (prostate and central nervous system). The number of autopsies ranged between 1 and 246 with a total of 823 autopsies performed. The most frequent cancer discovered at autopsy was lymphoma (n = 13, 15%), followed by renal cell carcinoma (RCC) (n = 11, 13%), non-small cell lung cancer (NSCLC) (n = 10, 11%), melanoma (n = 10, 11%), choriocarcinoma (n = 6, 7%) and glioblastoma (GBM) (n = 6, 7%). CONCLUSIONS:Lymphoma and melanoma are still difficult-to-detect cancers both during donor investigation and at procurement, whilst prostate cancer and choriocarcinoma are almost always easily detected nowadays thank to blood markers and clinical examination. There have been improvements with time in pre-donation detection procedures which are now working well, particularly when complete imaging investigations are performed, given that detection rate of CT/MRI is high and accurate. Autopsy can play a role to help to establish the correct donor management pathways in case of cancer discover. Furthermore, it helps to better understand which cancers are still eluding detection and consequently to refine guidelines' assessment procedures.
PMID: 33647551
ISSN: 1557-9816
CID: 5127002

Survival implications of prescription opioid and benzodiazepine use in lung transplant recipients: Analysis of linked transplant registry and pharmacy fill records

Lentine, Krista L; Salvalaggio, Paolo R; Caliskan, Yasar; Lam, Ngan N; McAdams-DeMarco, Mara; Axelrod, David; Segev, Dorry L; Myaskovsky, Larissa; Dew, Mary Amanda; Bruschwein, Heather; Levine, Deborah J; Sweet, Stuart; Hess, Gregory P; Kasiske, Bertram L; Schnitzler, Mark A
BACKGROUND:Prescription opioid and benzodiazepine use have been associated with morbidity and mortality among some groups of solid organ transplant recipients, but implications for outcomes among lung transplant patients are not well described. METHODS:). RESULTS:). These effects were independent, and interactions were not detected. CONCLUSIONS:Benzodiazepine prescription fills before and after lung transplant, and opioid fills after transplant, are independently associated with posttransplant mortality. Review of benzodiazepine and opioid use history is relevant to risk-stratifying patients before and after lung transplant.
PMCID:8169588
PMID: 33846078
ISSN: 1557-3117
CID: 5127102

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Boyarsky, Brian J; Werbel, William A; Avery, Robin K; Tobian, Aaron A R; Massie, Allan B; Segev, Dorry L; Garonzik-Wang, Jacqueline M
PMID: 33720292
ISSN: 1538-3598
CID: 5127032

The Precise Relationship Between Model for End-Stage Liver Disease and Survival Without a Liver Transplant

VanDerwerken, Douglas N; Wood, Nicholas L; Segev, Dorry L; Gentry, Sommer E
BACKGROUND AND AIMS:Scores from the Model for End-Stage Liver Disease (MELD), which are used to prioritize candidates for deceased donor livers, are widely acknowledged to be negatively correlated with the 90-day survival rate without a liver transplant. However, inconsistent and outdated estimates of survival probabilities by MELD preclude useful applications of the MELD score. APPROACH AND RESULTS:Using data from all prevalent liver waitlist candidates from 2016 to 2019, we estimated 3-day, 7-day, 14-day, 30-day, and 90-day without-transplant survival probabilities (with confidence intervals) for each MELD score and status 1A. We used an adjusted Kaplan-Meier model to avoid unrealistic assumptions and multiple observations per person instead of just the observation at listing. We found that 90-day without-transplant survival has improved over the last decade, with survival rates increasing >10% (in absolute terms) for some MELD scores. We demonstrated that MELD correctly prioritizes candidates in terms of without-transplant survival probability but that status 1A candidates' short-term without-transplant survival is higher than that of MELD 40 candidates and lower than that of MELD 39 candidates. Our primary result is the updated survival functions themselves. CONCLUSIONS:We calculated without-transplant survival probabilities for each MELD score (and status 1A). The survival function is an invaluable tool for many applications in liver transplantation: awarding of exception points, calculating the relative demand for deceased donor livers in different geographic areas, calibrating the pediatric end-stage liver disease score, and deciding whether to accept an offered liver.
PMID: 33655565
ISSN: 1527-3350
CID: 5127012

High-dose opioid utilization and mortality among individuals initiating hemodialysis

Daubresse, Matthew; Alexander, G Caleb; Crews, Deidra C; Segev, Dorry L; Lentine, Krista L; McAdams-DeMarco, Mara A
BACKGROUND:Individuals undergoing hemodialysis in the United States frequently report pain and receive three-fold more opioid prescriptions than the general population. While opioid use is appropriate for select patients, high-dose utilization may contribute to an increased risk of death due to possible accumulation of opioid metabolites. METHODS:We studied high-dose opioid utilization (≥120 morphine milligram equivalents [MME] per day) among adults initiating hemodialysis in the United States between 2007 and 2014 using national registry data. We calculated the cumulative incidence (%) of high-dose utilization and depicted trends in the average percentage of days individuals were exposed to opioids. We used adjusted Cox proportional hazards models to identify which opioid doses were associated with mortality. RESULTS:Among 327,344 adults undergoing hemodialysis, the cumulative incidence of high-dose utilization was 14.9% at 2 years after initiating hemodialysis. Among patients with ≥1 opioid prescription during follow-up, the average percentage of days exposed to high-dose utilization increased from 13.9% in 2007 to 26.1% in 2014. Compared to 0MME per day, doses < 60MME were not associated with an increased risk of mortality, but high-dose utilization was associated with a 1.63-fold (95% CI, 1.57, 1.69) increased risk of mortality. The risk of mortality associated with opioid dose was highest in the first year after hemodialysis initiation. CONCLUSIONS:The risk of mortality associated with opioid utilization among individuals on hemodialysis increases as doses exceed 60MME per day and is greatest during periods of high-dose utilization. Patients and clinicians should carefully weigh the risks and benefits of opioid doses exceeding 60MME per day.
PMID: 33622271
ISSN: 1471-2369
CID: 5126992

Trends in Heart and Lung Transplantation in the United States Across the COVID-19 Pandemic

Hallett, Andrew; Motter, Jennifer D; Frey, Alena; Higgins, Robert S; Bush, Errol L; Snyder, Jon; Garonzik-Wang, Jacqueline M; Segev, Dorry L; Massie, Allan B
The coronavirus disease 2019 (COVID-19) pandemic has had a variable course across the United States. Understanding its evolving impact on heart and lung transplantation (HT and LT) will help with planning for next phases of this pandemic as well as future ones.
PMCID:8425844
PMID: 34514114
ISSN: 2373-8731
CID: 5127642

Kidney Disease Symptoms before and after Kidney Transplantation

Taylor, Kathryn; Chu, Nadia M; Chen, Xiaomeng; Shi, Zhan; Rosello, Eileen; Kunwar, Sneha; Butz, Paul; Norman, Silas P; Crews, Deidra C; Greenberg, Keiko I; Mathur, Aarti; Segev, Dorry L; Shafi, Tariq; McAdams-DeMarco, Mara A
BACKGROUND AND OBJECTIVES:Patients with kidney failure report a high symptom burden, which likely increases while on dialysis due to physical and mental stressors and decreases after kidney transplantation due to restoration of kidney function. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS:=190), and post-transplantation symptom score trajectories (mixed effects models). RESULTS:At evaluation, candidates reported being moderately to extremely bothered by fatigue (32%), xeroderma (27%), muscle soreness (26%), and pruritus (25%); 16% reported high and 21% reported very high symptom burden. Candidates with very high symptom burden were at greater waitlist mortality risk (adjusted subdistribution hazard ratio, 1.67; 95% confidence interval, 1.06 to 2.62). By transplantation, 34% experienced an increased symptom burden, whereas 42% remained unchanged. The estimated overall symptom score was 82.3 points at transplantation and 90.6 points at 3 months (10% improvement); the score increased 2.75 points per month (95% confidence interval, 2.38 to 3.13) from 0 to 3 months, and plateaued (-0.06 points per month; 95% confidence interval, -0.30 to 0.18) from 3 to 12 months post-transplantation. There were early (first 3 months) improvements in nine of 11 symptoms; pruritus (23% improvement) and fatigue (21% improvement) had the greatest improvements. CONCLUSIONS:Among candidates, very high symptom burden was associated with waitlist mortality, but for those surviving and undergoing kidney transplantation, symptoms improved.
PMID: 34597266
ISSN: 1555-905x
CID: 5127702

Pretransplant Hepatitis C Virus Treatment Decreases Access to High-quality Livers

Strauss, Alexandra T; Ishaque, Tanveen; Weeks, Sharon; Hamilton, James P; Simsek, Cem; Durand, Christine M; Massie, Allan B; Segev, Dorry L; Gurakar, Ahmet; Garonzik-Wang, Jacqueline M
Background/UNASSIGNED:Despite the revolutionary role of direct-acting antivirals for hepatitis C virus (HCV), the treatment timing for liver transplant candidates remains controversial. We hypothesize that deferring treatment until after liver transplantation improves access to a larger and higher-quality donor pool without a detrimental impact on post-liver transplantation outcomes. Methods/UNASSIGNED:This single-center study includes recipients that underwent deceased-donor liver transplant with HCV as the primary indication January 1, 2014, to December 31, 2018. For recipients that were untreated (n = 87) versus treated (n = 42) pre-LT, we compared post-LT mortality using Cox regression with inverse probability of treatment-weighted data. Results/UNASSIGNED: = 0.06). Conclusions/UNASSIGNED:Deferring HCV treatment improves access to higher-quality donors and may improve post-LT survival.
PMCID:8440014
PMID: 34549082
ISSN: 2373-8731
CID: 5127662